Product Description
Plonmarlimab (or TJM2) is an internally discovered neutralizing antibody against human GM-CSF, an important cytokine that plays a critical role in chronic inflammation and destruction in autoimmune diseases such as RA GM-CSF can polarize macrophages into the pro-inflammatory M1 phenotype and is known to induce an inflammatory cascade involving other pro-inflammatory cytokines such as tumor-necrosis factor (TNF), interleukin-1 (IL-1), IL-6, IL-12, and IL-23.
Mechanisms of Action: GM-CSF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: I-Mab Biopharma
Company Location: SHANGHAI F4 201210
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: COVID-19
Phase 2: Lymphohistiocytosis, Hemophagocytic|Macrophage Activation Syndrome
Phase 1: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TJ003234COV201 | P3 |
Completed |
COVID-19 |
2022-02-07 |
39% |
| CTR20200952 | P1 |
Recruiting |
Arthritis, Rheumatoid |
None |
|
| CTR20230579 | P2 |
Not yet recruiting |
Macrophage Activation Syndrome|Lymphohistiocytosis, Hemophagocytic |
None |